信迪利单抗一线治疗晚期胃癌或胃食管结合部腺癌的疗效分析

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1053 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To retrospectively analyze the efficacy of sintilimab combined with chemotherapy in the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma(GC or GEJC). Methods Clinical data of patients with advanced GC or GEJC who received first-line sintilimab combined with chemotherapy at the First Medical Center of the Chinese PLA General Hospital from January 2019 to October 2022 were collected. Median progression-free survival (mPFS), objective response rate (ORR), and disease control rate (DCR) of enrolled patients were retrospectively analyzed. Results A total of 71 patients were included, with a median age of 60, including 53 males and 18 females. Forty-five patients were treated with sintilimab combined with oxaliplatin based regimen, while 26 patients were treated with sintilimab combined with albumin-bound paclitaxel (nab-paclitaxel) based regimen. The ORR, DCR and mPFS of all patients were 67.6%, 97.2% and 11.2 months (95% CI 9.7-12.8), respectively. The ORR, DCR and mPFS of oxaliplatin-based combination group were 73.3%, 97.8% and 11.3 months (95%CI 5.5-17.2), while the ORR, DCR and mPFS of nab-paclitaxel-based combination group were 57.7%, 96.2% and 10.9 months (95%CI 9.0-12.9). There was no significant difference in ORR and PFS between the two groups. Conclusions The first-line application of sintilimab combined with chemotherapy in advanced GC or GEJC can significantly benefit the mPFS of patients. In addition, the efficacy of sintilimab combined with nab-paclitaxel-based treatment is comparable with that with oxaliplatin-based treatment.

Key words： gastric cancer sintilimab first-line treatment Oxaliplatin nab-paclitaxel

Received: 20 December 2022

ZTFLH:

R735.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Juan
	YE Sisi
	ZHANG Pengfei
	BAI Li

Cite this article:

LI Juan,YE Sisi,ZHANG Pengfei等. Efficacy of sintilimab combined with chemotherapy in the first-line treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(6): 476-480.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2023/V34/I6/476

[1]	Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021,71(3): 209-249.
[2]	Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries?[J]. Lancet Glob Health, 2018,6(5): e555-e567.
[3]	Janjigian Y Y, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial?[J]. Lancet, 2021,398(10294): 27-40.
[4]	Xu J, Jiang H, Pan Y, et al. LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase Ⅲ study?[J]. Annals of Oncology, 2021,32: S1331.
[5]	Boku N, Ryu M H, Kato K, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) [J]. Ann Oncol, 2019,30(2): 250-258.
[6]	Shitara K, Cutsem E, Bang Y J, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(10):1571-1580.
[7]	Sun J M, Shen L, Shah M A, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771.
[8]	Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J]. N Engl J Med, 2006,355(24): 2542-2550.
[9]	Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J]. N Engl J Med, 2007,357(26): 2666-2676.
[10]	Ozols R F, Bundy B N, Greer B E, et al. Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer: a Gynecologic Oncology Group study[J]. J Clin Oncol, 2003,21(17): 3194-3200.
[11]	Dai Y H, Yu X J, Xu H T, et al. Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase Ⅲ trial (GAPSO study)[J]. Ther Adv Med Oncol, 2022,14: 17588359221118020.
[12]	Högner A, Breithaupt K, Stein A, et al. RAP: a phase Ⅱ trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO)[J]. J Clin Oncol, 2019, 37(15_suppl): TPS4148-TPS4148.
[13]	Liu T, Bai Y, Lin X, et al. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis[J]. Int J Cancer, 2023, 152(4): 749-760.
[14]	Janjigian Y Y, Kawazoe A, Yanez P E, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study[J].J Clin Oncol, 2021, 39(15_suppl): 4013.
[15]	Chen L T, Satoh T, Ryu M H, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data[J]. Gastric Cancer, 2020,23(3): 510-519.
[16]	Kang Y K, Chen L T, Ryu M H, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2022,23(2): 234-247.
[17]	Wang F, Wei X L, Wang F H, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432[J]. Ann Oncol, 2019,30(9): 1479-1486.
[18]	Jiang H, Yu X, Li N, et al. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study[J]. J Immunother Cancer, 2022, 10(3).1365-1368.
[19]	Guo H, Ding P, Sun C, et al. Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: a single-arm, open-label, phase Ⅱ trial?[J]. Front Oncol, 2022,12: 927781.
[20]	He M M, Wang F, Jin Y, et al. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer?[J]. Cancer Sci, 2018,109(11): 3575-3582.
[21]	Peng Z, Wei J, Wang F, et al. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma[J]. Clin Cancer Res, 2021,27(11): 3069-3078.